2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Blood Cholesterol: Executive Summary
2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Blood Cholesterol: Executive Summary
复制标题
DOI：
10.1161/cir.0000000000000625
复制
发表时间：
2019-06-25
影响因子：
24
通讯作者：
Wijeysundera, Duminda N.
中科院分区：
文献类型：
--
作者：
Grundy, Scott M.;Stone, Neil J.;Wijeysundera, Duminda N.
本指南中列出的建议尽可能以证据为基础。从1980年5月至2017年7月进行了初步广泛的证据审查，包括来自涉及人类受试者的研究的文献，以英语发表，并在MEDLINE（通过PubMed）、EMBASE、科克伦图书馆、医疗保健研究和质量管理局以及与本指南相关的其他选定数据库中检索。关键检索词包括但不限于：高脂血症、胆固醇、LDL-C、HDL-C、依折麦布、胆汁酸螯合剂、PCSK 9抑制剂、生活方式、饮食、运动、药物、儿童、青少年、筛选、一级预防、二级预防、心血管疾病、冠状动脉钙、家族性高胆固醇血症。ASCVD风险增强因素，他汀类药物治疗，糖尿病，女性，依从性，西班牙裔/拉丁裔，南亚人，非裔美国人。编写委员会还考虑了指南编写过程中截至2018年8月发表的其他相关研究，并在适当时将其添加到证据表中。最终证据表包含在在线数据补充中，并总结了编写委员会用于制定建议的证据。本文件中选择和发表的参考文献具有代表性，但不包括所有参考文献。如序言的详细版本所述，委托独立的证据审查委员会对胆固醇相关的关键临床问题进行正式的系统审查（表1），编写委员会考虑将其结果纳入本指南。与此同时，编写委员会成员评估了与指南其余部分相关的研究数据。正式提出并讨论了证据审查委员会和编写委员会成员的调查结果，然后提出了建议。2018年胆固醇临床实践指南（S1。1-1)与本指南一并发布，并包括其各自的数据补充。
The recommendations listed in the present guideline are, whenever possible, evidence based. An initial extensive evidence review, which included literature derived from research involving human subjects, published in English, and indexed in MEDLINE (through PubMed), EMBASE, the Cochrane Library, the Agency for Healthcare Research and Quality, and other selected databases relevant to the present guideline, was conducted from May 1980 to July 2017. Key search words included but were not limited to the following: hyperlipidemia, cholesterol, LDL-C, HDL-C, ezetimibe, bile acid sequestrants, PCSK9 inhibitors, lifestyle, diet, exercise, medications, child, adolescent, screening, primary prevention, secondary prevention, cardiovascular disease, coronary artery calcium, familial hypercholesterolemia. ASCVD risk-enhancing factors, statin therapy, diabetes mellitus, women, adherence, Hispanic/Latino, South Asian, African American. Additional relevant studies published through August 2018 during the guideline writing process, were also considered by the writing committee and added to the evidence tables when appropriate. The final evidence tables are included in the Online Data Supplement and summarize the evidence used by the writing committee to formulate recommendations. References selected and published in the present document are representative and not all-inclusive.As noted in the detailed version of the Preamble, an independent evidence review committee was commissioned to perform a formal systematic review of critical clinical questions related to cholesterol (Table 1), the results of which were considered by the writing committee for incorporation into the present guideline. Concurrent with this process, writing committee members evaluated study data relevant to the rest of the guideline. The findings of the evidence review committee and the writing committee members were formally presented and discussed, and then recommendations were developed. The systematic review for the 2018 Cholesterol Clinical Practice Guidelines (S1. 1-1) is published in conjunction with the present guideline, and includes its respective data supplements.